Autologous engineered T cell receptor therapy in advanced cancer
ABSTRACTTo overcome challenges associated with adoptive cell therapy (ACT), we developed a personalized autologous T-cell therapy program. Patients with advanced cancer with HLA-A *02:01 allele and tumor expression of PRAME, MAGEA1, MAGEA4, MAGEA8, NY-ESO-1, COL6A3 exon 6, MXRA5, and/or MMP1 underwe...
Main Authors: | Apostolia M. Tsimberidou, Mehmet A. Baysal, Abhijit Chakraborty, Borje S. Andersson |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2023.2290356 |
Similar Items
-
Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer
by: Sarah Bazargan, et al.
Published: (2023-10-01) -
Іnfusion-transfusion therapy and inotropic support in patients with sepsis
by: S. D. Shapoval, et al.
Published: (2018-07-01) -
Rapid cell separation with minimal manipulation for autologous cell therapies
by: Smith, Alban J., et al.
Published: (2018) -
Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
by: Benno Lickefett, et al.
Published: (2023-12-01) -
Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma
by: Felix Korell, et al.
Published: (2021-04-01)